<?xml version="1.0"?>
<metadata xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dc="http://purl.org/dc/elements/1.1/"><dc:title>Quality of life in Slovenian patients with skull base tumours</dc:title><dc:creator>Vozel,	Domen	(Avtor)
	</dc:creator><dc:creator>Urbančič,	Jure	(Avtor)
	</dc:creator><dc:creator>Battelino,	Saba	(Avtor)
	</dc:creator><dc:creator>Božanić Urbančič,	Nina	(Avtor)
	</dc:creator><dc:creator>Steiner,	Nejc	(Avtor)
	</dc:creator><dc:creator>Felbabić,	Tomislav	(Avtor)
	</dc:creator><dc:creator>Bošnjak,	Roman	(Avtor)
	</dc:creator><dc:subject>quality of life</dc:subject><dc:subject>skull base</dc:subject><dc:subject>neoplasms</dc:subject><dc:subject>meningioma</dc:subject><dc:subject>carcinoma</dc:subject><dc:description>Background: Skull base tumours frequently manifest as severe physical morbidity and quality of life (QoL) impairment. The disease-related QoL measurement can be performed with disease specific questionnaires, e.g. Skull base inventory (SBI). Patients and methods: The study consisted of two parts: (1) cross-cultural adaptation and psychometric testing of the Slovenian SBI (SBI-SLO) and (2) QoL assessment in skull base tumours. Two groups completed the SBI-SLO: 1.) adult patients without prior treatment of anterior, anterolateral and/or central skull base and 2.) healthy controls. Patients with skull-base tumours were further analysed for difference in SBI-SLO total score and domain scores between 1.) benign and malignant tumours and 2.) pituitary macroadenomas and other benign tumours. Results: 59 patients (46% male, 54% female, median age 57.7 years) and 47 subjects from control group (49% male, 51% female, median age 42,2 years) completed SBI-SLO, which demonstrated an excellent level of internal consistency (Cronbach's alpha = 0.924) and excellent test-retest reliability (intraclass correlation coefficient [ICCA] = 0.952). The discriminant validity was confirmed (p = 0.000). SBI-SLO total score, emotional, other and family domain scores were lower in malignant than in benign tumours (p = 0.031, p = 0.038, p = 0.008, and p = 0.046, respectively). Macroadenoma and other benign tumours differed only in neurological domain score (p &lt; 0.05). Conclusions: A skull base tumour, especially malignant, can exert a substantial detrimental effect on a patient's quality of life. The SBI is a key tool for assessing QoL, also available in Slovenian.</dc:description><dc:date>2026</dc:date><dc:date>2026-04-24 14:49:42</dc:date><dc:type>Neznano</dc:type><dc:identifier>29218</dc:identifier><dc:identifier>UDK: 616-006</dc:identifier><dc:identifier>ISSN pri članku: 1581-3207</dc:identifier><dc:identifier>DOI: 10.2478/raon-2026-0007</dc:identifier><dc:identifier>COBISS_ID: 266450435</dc:identifier><dc:language>sl</dc:language></metadata>
